Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed Glioblastoma
Principal Investigator
Tracy Batchelor, MD
Status
Terminated
Date Opened To Accrual
February 26 2010
Date Closed to Accrual
May 09 2012
Date of Study Termination
May 20 2022
Disease Site
Brain [BN]
Other
Phase
II
Developmental Therapeutics
No
Primary Objective
To determine if the addition of cediranib to chemoradiation treatment enhances treatment efficacy as measured by the 6-month progression-free survival rate.
Data Collection Notice:
Data for this trial is being collected via the NRG/RTOG Data Center.
Patient Population
Histopathologically confirmed glioblastoma (WHO Grade IV) confirmed by central review prior to Step 2 registration. Tumor tissue that is determined by central pathology review prior to Step 2 registration to be of sufficient size for analysis of MGMT status. The tumor must have a supratentorial component.
Target Accrual
283
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.